Ascendis Pharma A/S (NASDAQ:ASND) Given New $352.00 Price Target at TD Cowen

Ascendis Pharma A/S (NASDAQ:ASND) had its target price lifted by stock analysts at TD Cowen from $341.00 to $352.00 in a research note issued to investors on Friday, Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. TD Cowen‘s price objective points to a potential upside of 31.23% from the company’s previous close.

A number of other equities analysts have also issued reports on ASND. Jefferies Financial Group decreased their target price on shares of Ascendis Pharma A/S from $333.00 to $330.00 and set a “buy” rating for the company in a research report on Monday, August 31st. Wedbush restated an “outperform” rating and set a $327.00 price target on shares of Ascendis Pharma A/S in a research report on Tuesday, September 1st. UBS Group began coverage on shares of Ascendis Pharma A/S in a research report on Thursday, October 15th. They set a “buy” rating and a $269.00 price target on the stock. HC Wainwright reduced their price target on shares of Ascendis Pharma A/S from $344.00 to $335.00 and set a “buy” rating for the company in a research note on Friday. Finally, Royal Bank Of Canada increased their price objective on shares of Ascendis Pharma A/S from $280.00 to $290.00 and gave the company an “outperform” rating in a report on Friday, August 14th. Nineteen research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, Ascendis Pharma A/S currently has a consensus rating of “Moderate Buy” and a consensus price target of $307.10.

Ascendis Pharma A/S Stock Up 3.5%

ASND opened at $268.24 on Friday. Ascendis Pharma A/S has a 12 month low of $188.07 and a 12 month high of $282.15. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.99 and a quick ratio of 2.32. The stock has a market cap of $16.73 billion, a P/E ratio of 20.73 and a beta of 0.40. The stock’s 50 day moving average price is $242.58 and its 200 day moving average price is $239.65.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.68). The business had revenue of $387.22 million for the quarter, compared to analyst estimates of $376.75 million. Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%. As a group, research analysts predict that Ascendis Pharma A/S will post 3.43 earnings per share for the current year.

Insider Buying and Selling

In other Ascendis Pharma A/S news, SVP Mads Bodenhoff sold 3,000 shares of the company’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $270.19, for a total value of $810,570.00. Following the completion of the sale, the senior vice president directly owned 3,000 shares of the company’s stock, valued at approximately $810,570. This represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 40.00% of the company’s stock.

Hedge Funds Weigh In On Ascendis Pharma A/S

Several hedge funds have recently made changes to their positions in the business. First Trust Advisors LP boosted its holdings in Ascendis Pharma A/S by 435.8% during the third quarter. First Trust Advisors LP now owns 86,940 shares of the biotechnology company’s stock worth $19,807,000 after buying an additional 70,714 shares in the last quarter. Allianz SE increased its holdings in shares of Ascendis Pharma A/S by 219.4% in the third quarter. Allianz SE now owns 16,215 shares of the biotechnology company’s stock valued at $3,694,000 after buying an additional 11,138 shares in the last quarter. Advisors Asset Management Inc. bought a new position in shares of Ascendis Pharma A/S in the third quarter valued at $6,075,000. GW&K Investment Management LLC increased its holdings in shares of Ascendis Pharma A/S by 121.2% in the third quarter. GW&K Investment Management LLC now owns 564 shares of the biotechnology company’s stock valued at $128,000 after buying an additional 309 shares in the last quarter. Finally, USS Investment Management Ltd lifted its position in shares of Ascendis Pharma A/S by 21.0% during the 3rd quarter. USS Investment Management Ltd now owns 170,587 shares of the biotechnology company’s stock valued at $38,878,000 after acquiring an additional 29,577 shares during the last quarter.

Key Ascendis Pharma A/S News

Investors following ASND have been watching these news items:

• Positive Sentiment: Ascendis reported Q3 product revenue of €366 million, up 89% year over year, led by YORVIPATH at €291 million. The company also reported better-than-expected earnings and revenue, and said it expects at least €600 million in operating cash flow for the full year. Ascendis Pharma Reports Third Quarter 2026 Financial Results
• Neutral Sentiment: HC Wainwright lowered its price target from $344 to $335 but kept a Buy rating, indicating continued optimism while trimming its valuation view. HC Wainwright recommendations
• Neutral Sentiment: The company granted 28,030 employee warrants, which may have a modest dilutive effect. Ascendis Pharma Grants 28,030 Employee Warrants

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.